Bosutinib treatment for Philadelphia chromosome-positive leukemias.

Abstract

The SRC-ABL inhibitor bosutinib is one of the five tyrosine kinase inhibitors currently approved for the treatment of Philadelphia chromosome-positive leukemias. Bosutinib has shown activity against all phases of resistant chronic myeloid leukemia that do not harbor the T315I or V299L ABL kinase domain mutations. Bosutinib is overall well tolerated; transient diarrhea is the most common side effect. This article summarizes the pharmacokinetics, pharmacodynamics, safety and efficacy of bosutinib for the treatment of Philadelphia chromosome-positive leukemias.

• Authors: Beverly Bethelmie-Bryan, Katharine Lord, Stacie Holloway, Hanna Jean Khoury
• Journal: Future oncology (London, England) (Future Oncol) Vol. 10 Issue 2 Pg. 179-85 (Feb 2014) ISSN: 1744-8301 [Electronic] England
• PMID: 24490604 (Publication Type: Journal Article)

Chemical References

• Aniline Compounds
• Antineoplastic Agents
• Nitriles
• Protein Kinase Inhibitors
• Quinolines
• bosutinib

Topics

• Aniline Compounds (adverse effects, chemistry, pharmacology, therapeutic use)
• Antineoplastic Agents (adverse effects, chemistry, pharmacology, therapeutic use)
• Drug Approval (legislation & jurisprudence)
• Humans
• Leukemia (drug therapy, genetics, pathology)
• Neoplasm Staging
• Nitriles (adverse effects, chemistry, pharmacology, therapeutic use)
• Philadelphia Chromosome
• Protein Kinase Inhibitors (adverse effects, chemistry, pharmacology, therapeutic use)
• Quinolines (adverse effects, chemistry, pharmacology, therapeutic use)
• Treatment Outcome